MEN4
MCID: MLT086
MIFTS: 51

Multiple Endocrine Neoplasia, Type Iv (MEN4) malady

Categories: Genetic diseases, Endocrine diseases, Rare diseases, Gastrointestinal diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Multiple Endocrine Neoplasia, Type Iv

About this section

Aliases & Descriptions for Multiple Endocrine Neoplasia, Type Iv:

Name: Multiple Endocrine Neoplasia, Type Iv 52 11 12 68
Multiple Endocrine Neoplasia Type 4 11 24 54 13
Men4 24 54 70
 
Multiple Endocrine Neoplasia 4 70 27
Multiple Endocrine Neoplasia Type Iv 24
Men 4 24

Characteristics:

Orphanet epidemiological data:

54
multiple endocrine neoplasia type 4:
Inheritance: Autosomal dominant,Not applicable

HPO:

64
multiple endocrine neoplasia, type iv:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 610755
Disease Ontology11 DOID:0080137
Orphanet54 ORPHA276152
ICD10 via Orphanet31 D44.8
MedGen37 C1970712

Summaries for Multiple Endocrine Neoplasia, Type Iv

About this section
UniProtKB/Swiss-Prot:70 Multiple endocrine neoplasia 4: Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2.

MalaCards based summary: Multiple Endocrine Neoplasia, Type Iv, also known as multiple endocrine neoplasia type 4, is related to multiple endocrine neoplasia 1 and familial porencephaly, and has symptoms including Array, Array and Array. An important gene associated with Multiple Endocrine Neoplasia, Type Iv is CDKN1B (Cyclin Dependent Kinase Inhibitor 1B), and among its related pathways are Aryl Hydrocarbon Receptor Pathway and FoxO family signaling. Affiliated tissues include thyroid, pituitary and cervix, and related mouse phenotypes are Increased shRNA abundance (Z-score > 2) and integument.

Description from OMIM:52 610755

Related Diseases for Multiple Endocrine Neoplasia, Type Iv

About this section

Diseases in the Multiple Endocrine Neoplasia family:

Multiple Endocrine Neoplasia Iia Multiple Endocrine Neoplasia Iib
Multiple Endocrine Neoplasia 1 multiple endocrine neoplasia, type iv

Diseases related to Multiple Endocrine Neoplasia, Type Iv via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
idRelated DiseaseScoreTop Affiliating Genes
1multiple endocrine neoplasia 110.8
2familial porencephaly10.2AIP, CDKN1B
3spondyloepimetaphyseal dysplasia, isidor type10.2AIP, MEN1
4spondylometaphyseal dysplasia, czarny-ratajczak type10.2AIP, MEN1
5african histoplasmosis10.1AIP, PRL
6papillary adenoma10.1MEN1, PRKAR1A
7glaucoma, hereditary adult type 1a10.1AIP, PRL
8vertebral artery occlusion10.1AIP, PRL
9pituitary adenoma, acth-secreting10.1AIP, PRL
10protein s deficiency10.1AIP, PRL
11rheumatic encephalitis10.1MEN1, PRL
12infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations10.0AIP, PRL
13merkel cell carcinoma10.0PRKAR1A, PRL
14esophagus squamous cell papilloma10.0PRKAR1A, PRL
15cowper gland carcinoma10.0CDKN2C, MEN1
16urethra clear cell adenocarcinoma10.0MEN1, PRL
17adrenal cortical adenocarcinoma10.0PRKAR1A, PRL
18aneurysm10.0CDKN1B, MEN1, PRKAR1A
19subserous uterine fibroid10.0CDKN1B, MEN1, PRKAR1A
20uterine ligament cancer10.0AIP, MEN1, PRKAR1A
21multiple endocrine neoplasia10.0
22pulmonary neuroendocrine tumor10.0AIP, MEN1, PRL
23immune system organ benign neoplasm10.0AIP, MEN1, PRL
24endocrine organ benign neoplasm10.0AIP, MEN1, PRL
25parathyroid carcinoma10.0MEN1, PRKAR1A
26vestibular gland benign neoplasm10.0AIP, MEN1, PRL
27thrombophilia10.0AIP, MEN1, PRL
28osseous heteroplasia, progressive9.9MEN1, PRKAR1A, PRL
29extraocular retinoblastoma9.9CDK2, CDKN1B
30post-surgical hypoinsulinemia9.9CDK2, CDKN1B
31cone-rod dystrophy 59.8AIP, CDKN1B, MEN1, PRKAR1A
32integumentary system benign neoplasm9.8CDK2, CDKN1B
33cold-induced sweating syndrome 29.8AIP, MEN1, PRKAR1A, PRL
34adamantinous craniopharyngioma9.8AIP, MEN1, PRKAR1A, PRL
35bladder colonic type adenocarcinoma9.8AIP, MEN1, PRKAR1A, PRL
36leukemia, acute promyelocytic, somatic9.6CDKN1B, CDKN2C, MEN1, PRKAR1A, PRL
37bowen-conradi syndrome9.1AIP, CDK2, CDKN1B, CDKN2C, MEN1, PRKAR1A

Graphical network of the top 20 diseases related to Multiple Endocrine Neoplasia, Type Iv:



Diseases related to multiple endocrine neoplasia, type iv

Symptoms & Phenotypes for Multiple Endocrine Neoplasia, Type Iv

About this section

Symptoms by clinical synopsis from OMIM:

610755

Clinical features from OMIM:

610755

Human phenotypes related to Multiple Endocrine Neoplasia, Type Iv:

 54 64 (show all 39)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the endocrine system54 Very frequent (99-80%)
2 hyperparathyroidism54 Very frequent (99-80%)
3 parathyroid adenoma64 54 Very frequent (99-80%) HP:0002897
4 hypercalcemia54 Very frequent (99-80%)
5 elevated circulating parathyroid hormone level54 Very frequent (99-80%)
6 parathyroid hyperplasia54 Very frequent (99-80%)
7 hyperinsulinemic hypoglycemia54 Frequent (79-30%)
8 growth hormone excess64 54 Frequent (79-30%) HP:0000845
9 thyroid adenoma54 Frequent (79-30%)
10 subcutaneous lipoma54 Frequent (79-30%)
11 diarrhea54 Frequent (79-30%)
12 zollinger-ellison syndrome54 Frequent (79-30%)
13 episodic abdominal pain54 Frequent (79-30%)
14 pituitary adenoma64 54 Frequent (79-30%) HP:0002893
15 peptic ulcer54 Frequent (79-30%)
16 pituitary prolactin cell adenoma54 Frequent (79-30%)
17 renal angiomyolipoma64 54 Frequent (79-30%) HP:0006772
18 adrenocortical adenoma54 Frequent (79-30%)
19 fasting hyperinsulinemia54 Frequent (79-30%)
20 angiofibromas54 Frequent (79-30%)
21 pituitary growth hormone cell adenoma54 Frequent (79-30%)
22 pituitary null cell adenoma54 Frequent (79-30%)
23 abnormality of pancreas physiology54 Frequent (79-30%)
24 insulinoma54 Frequent (79-30%)
25 pulmonary carcinoid tumor54 Frequent (79-30%)
26 esophagitis54 Frequent (79-30%)
27 neuroendocrine neoplasm54 Frequent (79-30%)
28 hypercortisolism54 Occasional (29-5%)
29 parathyroid carcinoma54 Occasional (29-5%)
30 confetti-like hypopigmented macules54 Occasional (29-5%)
31 pituitary corticotropic cell adenoma54 Occasional (29-5%)
32 erythema54 Occasional (29-5%)
33 testicular neoplasm54 Occasional (29-5%)
34 increased urinary cortisol level54 Occasional (29-5%)
35 extrahepatic cholestasis54 Occasional (29-5%)
36 cervix cancer54 Occasional (29-5%)
37 increased glucagon level54 Occasional (29-5%)
38 carcinoid tumor64 54 Occasional (29-5%) HP:0100570
39 thymoma54 Very rare (<4-1%)

GenomeRNAi Phenotypes related to Multiple Endocrine Neoplasia, Type Iv according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-1928.7CDK2, MEN1, PRKAR1A

MGI Mouse Phenotypes related to Multiple Endocrine Neoplasia, Type Iv according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107717.8AIP, CDK2, CDKN1B, CDKN2C, PRL
2MP:00053897.7CDK2, CDKN1B, CDKN2C, MEN1, PRKAR1A, PRL
3MP:00053847.5AIP, CDK2, CDKN1B, CDKN2C, MEN1, PRKAR1A
4MP:00053787.5AIP, CDK2, CDKN1B, CDKN2C, MEN1, PRKAR1A
5MP:00053707.5AIP, CDK2, CDKN1B, MEN1, PRKAR1A, PRL
6MP:00053857.5AIP, CDK2, CDKN1B, CDKN2C, MEN1, PRKAR1A
7MP:00053877.4CDK2, CDKN1B, CDKN2C, MEN1, PRKAR1A, PRL
8MP:00020067.3AIP, CDK2, CDKN1B, CDKN2C, MEN1, PRKAR1A
9MP:00053767.1AIP, CDK2, CDKN1B, CDKN2C, MEN1, PRKAR1A
10MP:00053796.9AIP, CDK2, CDKN1B, CDKN2C, MEN1, PRKAR1A

Drugs & Therapeutics for Multiple Endocrine Neoplasia, Type Iv

About this section

Drugs for Multiple Endocrine Neoplasia, Type Iv (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 246)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
MetforminapprovedPhase 4, Phase 3, Phase 21803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
2
LiraglutideapprovedPhase 4, Phase 3329204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
3
Insulin LisproapprovedPhase 4240133107-64-9
Synonyms:
Insulin lispro (genetical recombination)
Insulin lispro (rDNA origin)
Insulin lispro protamine
 
Insulin lispro protamine recombinant
Insulin lispro recombinant
Insulin,lispro,human/rDNA
Insulin,lispro,protamine/rDNA
4
ZincapprovedPhase 422967440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
5
Insulin GlargineapprovedPhase 4528160337-95-1
Synonyms:
 
Insulin Glargine (rDNA origin)
Insulin glargine recombinant
6
SomatostatinapprovedPhase 423738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
7
Sirolimusapproved, investigationalPhase 4194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
8
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
9
EverolimusapprovedPhase 41940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
10Hormone AntagonistsPhase 4, Phase 3, Phase 1, Phase 213180
11HIV Protease InhibitorsPhase 4, Phase 3, Phase 2, Phase 15470
12IncretinsPhase 4, Phase 31579
13Sitagliptin PhosphatePhase 4, Phase 3423
14
protease inhibitorsPhase 4, Phase 3, Phase 2, Phase 15471
Synonyms:
 
protease inhibitors
15Dipeptidyl-Peptidase IV InhibitorsPhase 4, Phase 3862
16Hypoglycemic AgentsPhase 4, Phase 3, Phase 25896
17Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 1, Phase 213168
18HormonesPhase 4, Phase 3, Phase 1, Phase 214415
19insulinPhase 4, Phase 2, Phase 14646
20Insulin, IsophanePhase 4252
21Insulin, Globin ZincPhase 4, Phase 2, Phase 14645
22Immunosuppressive AgentsPhase 4, Phase 2, Phase 113086
23Isophane Insulin, HumanPhase 4151
24Isophane insulin, beefPhase 4151
25Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 122062
26Antibiotics, AntitubercularPhase 4, Phase 1, Phase 27180
27Anti-Bacterial AgentsPhase 4, Phase 3, Phase 1, Phase 211226
28Antifungal AgentsPhase 4, Phase 13696
29
Paclitaxelapproved, vet_approvedPhase 3, Phase 2, Phase 1286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
30
CarboplatinapprovedPhase 3, Phase 2205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
31
Estradiolapproved, investigational, vet_approvedPhase 3131850-28-25757, 53477783
Synonyms:
(+)-3,17b-Estradiol
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17beta)-Estra-1,3,5(10)-triene-3,17-diol
.alpha.-Estradiol
.alpha.-Oestradiol
.beta.-Estradiol
.beta.-Oestradiol
1,3,5[10]-Estratriene-3,17beta-diol 3-sulfate
1,3,5[10]-Estratriene-3,17beta-diol 3-sulphate
13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol
17 beta-Estradiol
17-.BETA.-Estradiol
17-E
17-beta
17-beta-OH-estradiol
17-beta-estradiol
17.beta.-Estradiol
17.beta.-Oestradiol
17E
17b-Estradiol
17b-Oestradiol
17beta Oestradiol
17beta oestradiol
17beta-Estra-1,3,5(10)-triene-3,17-diol
17beta-Estradiol
17beta-Oestradiol
1jgl
1qkt
1qku
2d06
3,17-Epidihydroxyestratriene
3,17-beta-Estradiol
3,17-beta-Oestradiol
3,17.beta.-Estradiol
3,17b-Dihydroxyestra-1,3,5(10)-triene
3,17b-Estradiol
3,17beta-Estradiol
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulfate
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulphate
50-28-2
73459-61-7
873662-39-6
AC-10460
AC1L1L2K
Aerodiol
Agofollin
Alora
Altrad
Amnestrogen
Aquadiol
B-Estradiol
BEDOs
BIDD:ER0125
BIDD:PXR0065
BPBio1_000532
BSPBio_000482
BSPBio_001065
Bardiol
Benzhormovarine
Beta-estradiol
Bio-0812
Bio-E-Gel
Bio1_000403
Bio1_000892
Bio1_001381
Bio2_000363
Bio2_000843
C00951
C18H24O2
CCRIS 280
CHEBI:16469
CHEMBL135
CID5757
CMC_11154
CPD-352
CPD000059126
Climaderm
Climara
Climara (TN)
Climara Forte
Compudose
Compudose 200
Compudose 365
Corpagen
D-3,17beta-Estradiol
D-Estradiol
D-Oestradiol
D00105
DB00783
Dermestril
Destradiol
Dihydro-Theelin
Dihydrofollicular hormone
Dihydrofolliculin
Dihydromenformon
Dihydrotheelin
Dihydroxyesterin
Dihydroxyestrin
Dihydroxyoestrin
Dimenformon
Diogyn
Diogynets
Divigel
Divigel (TN)
E 2
E 8875
E(sub 2)
E0025
E1024_SIGMA
E1132_SIGMA
E2257_SIGMA
E2758_SIGMA
E8875_SIGMA
EINECS 200-023-8
EU-0100503
Elestrin
Encore
Epiestriol 50
Esclim
Estra-1,3,5(10)-triene-3,17b-diol
Estrace
Estrace (TN)
Estraderm
Estraderm (TN)
Estraderm MX
Estraderm TTS
Estraderm TTS 100
Estraderm TTS 50
Estradiol
Estradiol [USAN:INN]
Estradiol-17 beta
Estradiol-17-beta
Estradiol-17.beta.
Estradiol-17beta
Estradiol-3,17beta
Estradiolo
Estradiolo [DCIT]
Estradiolum
Estradiolum [INN]
Estradot
Estraldine
Estrapak 50
Estrasorb
Estrasorb (TN)
Estreva
Estrifam
Estring
Estring (TN)
Estring Vaginal Ring
Estring vaginal ring
Estroclim
Estroclim 50
Estrodiolum
Estrofem 2
Estrofem Forte
Estrogel
 
Estrogel (TN)
Estrogel HBF
Estrovite
Evamist
Evorel
Extrasorb
Femanest
Femestral
Femestrol
Femogen
Fempatch
Femtrace
Femtran
Follicyclin
Gelestra
Ginedisc
Ginosedol
GynPolar
Gynergon
Gynestrel
Gynodiol
Gynoestryl
HMS1362E07
HMS1569I04
HMS1792E07
HMS1990E07
HMS2051C17
HMS2090E18
HSDB 3589
IDI1_002118
Innofem
Innofem (TN)
KBio2_000405
KBio2_002269
KBio2_002973
KBio2_004837
KBio2_005541
KBio2_007405
KBio3_000769
KBio3_000770
KBio3_002749
KBioGR_000405
KBioGR_002269
KBioSS_000405
KBioSS_002270
LMST02010001
LS-137
Lamdiol
Lio-Oid
Lopac0_000503
MLS000069494
MLS000758312
MLS001076331
Macrodiol
Macrol
Menest
Menorest
Menostar
Microdiol
MolPort-001-794-632
NCGC00091544-00
NCGC00091544-01
NCGC00091544-02
NCGC00091544-04
NCGC00091544-05
NCGC00091544-06
NCGC00091544-07
NCGC00091544-08
NCGC00091544-09
NCGC00091544-12
NCGC00179321-01
NCGC00179321-02
NSC-9895
NSC9895
Nordicol
Oesclim
Oestergon
Oestra-1,3,5(10)-triene-3,17b-diol
Oestradiol
Oestradiol Berco
Oestradiol R
Oestradiol-17-beta
Oestradiol-17.beta.
Oestradiol-17beta
Oestradiolum
Oestrogel
Oestroglandol
Oestrogynal
Ovahormon
Ovasterol
Ovastevol
Ovociclina
Ovocyclin
Ovocycline
Ovocylin
Perlatanol
Polyestradiol
Prestwick0_000441
Prestwick1_000441
Prestwick2_000441
Prestwick3_000441
Prestwick_207
Primofol
Profoliol
Profoliol B
Progynon
Progynon DH
Progynon-DH
S-21400
S1709_Selleck
SAM001247032
SK-Estrogens
SL-1100
SMP1_000121
SMR000059126
SPBio_002421
Sandrena 1
Sandrena Gel
Sisare Gel
Spectrum5_002055
Syndiol
Systen
Tradelia
Trial SAT
Trocosone
UNII-4TI98Z838E
VIVELLE-DOT
Vagifem
Vagifem (TN)
Vivelle
Vivelle (TN)
Zerella
Zesteem
Zesteen
Zumenon
[2,4,6,7-3H]-E2
[3H]-estradiol
[3H]]estradiol
b-Estradiol
beta-Estradiol
beta-Estradiol 3-sulfate
beta-Estradiol 3-sulphate
bmse000642
cMAP_000005
cis-Estradiol
cis-Oestradiol
component of Menrium
delta-Estradiol
delta-Oestradiol
estradiol
estradiol-17beta
nchembio.168-comp3
nchembio.76-comp2
nchembio775-comp2
nchembio794-comp6
nchembio860-comp1
progynon
32
NorgestimateapprovedPhase 338535189-28-76540478
Synonyms:
(+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester)
(17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
(17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
(3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate
35189-28-7
AC-655
AC1O712U
C017576
CHEBI:50815
CHEMBL1200934
CID6540478
D 138
D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-one oxime
D05209
DB00957
Dexnorgestrel Acetime
Dexnorgestrel acetime
I14-9729
 
LS-62080
NCGC00181353-01
NORGESTIMATE
Norgestimate (USP/INN)
Norgestimate [USAN:INN:BAN]
Norgestimato
Norgestimato [INN-Spanish]
Norgestimatum
Norgestimatum [INN-Latin]
ORF 10131
ORF-10131
Ortho-Prefest
RWJ 10131
RWJ-10131
UNII-C291HFX4DY
ZINC03938695
[(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
d-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime
d-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-one oxime
norgestrel oxime acetate
33
Moxifloxacinapproved, investigationalPhase 3431354812-41-2, 151096-09-2152946
Synonyms:
(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
151096-09-2
186826-86-8
192927-63-2
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
AC1L49EP
Actira (*Hydrochloride*)
Avelox
Avelox (*Hydrochloride*)
Avelox I.V.
BAY 12-8039
 
BAY 12-8039 (*Hydrochloride*)
CCRIS 8690
CHEMBL32
CID152946
DB00218
I06-1961
LS-141510
MFX
MXF
MXFX
Moxifloxacin [INN:BAN]
UNII-U188XYD42P
Vigamox
moxifloxacin
34
Ethinyl EstradiolapprovedPhase 372857-63-65991
Synonyms:
17 alpha-Ethinylestradiol
17 alpha-Ethynylestradiol
17 alpha-Ethynyloestradiol
17 alpha-ethinyestradiol
17-Ethinyl-3,17-estradiol
17-Ethinyl-3,17-oestradiol
17-Ethinylestradiol
17-Ethynylestradiol
17-Ethynylestradiol ram
17-Ethynyloestradiol
17-alpha-Ethinyl-17-beta-estradiol
17-alpha-Ethynyl-17-beta-oestradiol
17-alpha-Ethynylestradiol
17-alpha-Ethynylestradiol-17-beta
17-alpha-ethynyl estradiol
17-ethinyl-3,17-estradiol
17-ethinyl-3,17-oestradiol
17-ethinylestradiol
17.alpha.-Ethinyl-17.beta.-estradiol
17.alpha.-Ethinylestradiol
17.alpha.-Ethynyl-17.beta.-oestradiol
17.alpha.-Ethynylestradiol
17.alpha.-Ethynylestradiol-l7.beta.
17.alpha.-Ethynyloestradiol
17.alpha.-Ethynyloestradiol-17.beta.
17a-Ethinyl-17b-estradiol
17a-Ethinylestradiol
17a-Ethynyl-17b-oestradiol
17a-Ethynylestradiol
17a-Ethynylestradiol-l7b
17a-Ethynyloestradiol
17a-Ethynyloestradiol-17b
17alpha-Ethinyl estradiol
17alpha-Ethinylestradiol
17alpha-Ethinylestradiol-17beta
17alpha-Ethynylestradiol
17alpha-Ethynyloestradiol
17alpha-Ethynyloestradiol-17beta
17α-ethynylestradiol
406932-93-2
46263_FLUKA
46263_RIEDEL
57-63-6
77538-56-8
AC-2169
AC1L1LK6
AI3-52941
Aethinyloestradiolum
Aethinyoestradiol
Aethinyoestradiol [German]
Alora
Amenoron
Amenorone
Anovlar
BIDD:ER0162
BRN 2419975
Bio-0610
C07534
CCRIS 286
CHEBI:4903
CHEMBL691
CID5991
CPD000058319
Certostat
Chee-O-Gen
Chee-O-Genf
Cyclosa
D004997
D00554
DB00977
Dicromil
Diognat-E
Diogyn E
Diogyn-E
Diprol
Dyloform
E4876_SIGMA
EE
EE(sub 2)
EE2
EINECS 200-342-2
EO
ETHINYLESTRADIOL
Effik Brand of Ethinyl Estradiol
Ertonyl
Esclim
Esteed
Estigyn
Estinyl
Estinyl (TN)
Eston-E
Estopherol
Estoral
Estoral (Orion)
Estoral (VAN)
Estoral [Orion]
Estoral {[Orion]}
Estorals
Estradiol, Ethinyl
Estradiol, Ethynyl
Estring
Estrogen
Ethidol
Ethinoral
Ethinyl E2
Ethinyl Estradiol Hemihydrate
Ethinyl Estradiol [USP]
 
Ethinyl Estradiol, (8 alpha)-Isomer
Ethinyl Oestradiol Effik
Ethinyl estradiol
Ethinyl estradiol (USP)
Ethinyl-Oestradiol Effik
Ethinyl-Oestranol
Ethinyl-oestranol
Ethinylestradiol
Ethinylestradiol (JP15/INN)
Ethinylestradiol Jenapharm
Ethinylestradiol [INN:BAN:JAN]
Ethinylestradiolum
Ethinylestradiolum [INN-Latin]
Ethinylestriol
Ethinyloestradiol
Ethinyloestradiol [Steroidal oestrogens]
Ethy 11
Ethynyl estradiol
Ethynylestradiol
Ethynylestradiol, Ethinyl Estradiol
Ethynyloestradiol
Eticyclin
Eticyclol
Eticylol
Etinestrol
Etinestryl
Etinilestradiol
Etinilestradiol [INN-Spanish]
Etinilestradiolo
Etinilestradiolo [DCIT]
Etinoestryl
Etistradiol
Etivex
Evra
Feminone
Fempatch
Follicoral
Ginestrene
Gynodiol
Gynolett
HMS2051I19
HSDB 3587
Halodrin
Hemihydrate, Ethinyl Estradiol
Inestra
Innofem
Jenapharm Brand of Ethinyl Estradiol
Jenapharm, Ethinylestradiol
Kolpolyn
LMST02010036
LS-231
Linoral
Lynoral
MLS000028479
MLS000758274
Marvelon
Menolyn
Menostar
Mercilon
Microfollin
Microfollin Forte
MolPort-001-794-636
NCGC00091533-01
NCGC00091533-04
NCGC00091533-05
NCI60_000234
NSC-10973
NSC10973
Neo-Estrone
Nogest-S
Novestrol
OVULEN-21
OVULEN-28
Oradiol
Orestralyn
Orestrayln
Organon Brand of Ethinyl Estradiol
Ortho-Cyclen
Ovex
Oviol
PUBERTAL ETHINYL ESTRADIOL STUDY
Palonyl
Perovex
Primogyn
Primogyn C
Primogyn M
Progynon C
Progynon M
Prosexol
S1625_Selleck
SAM001247008
SGCUT00127
SMR000058319
Schering Brand of Ethinyl Estradiol
Spanestrin
Thiuram E
Thiuranide
UNII-423D2T571U
Vagifem
Varnoline
WLN: L E5 B666TTT&J E1 FQ F1UU1 OQ
Ylestrol
component of Demulen
component of Oracon
component of Ortrel
ethinyl estradiol
ethynyl estradiol
to_000048
35Antimitotic AgentsPhase 3, Phase 2, Phase 15657
36Albumin-Bound PaclitaxelPhase 3, Phase 2, Phase 12864
37Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 15602
38Topoisomerase InhibitorsPhase 3, Phase 1, Phase 25069
39Contraceptive AgentsPhase 3, Phase 1, Phase 21967
40Nucleic Acid Synthesis InhibitorsPhase 34962
41Polyestradiol phosphatePhase 31318
42Norgestimate, ethinyl estradiol drug combinationPhase 3433
43Estradiol 3-benzoatePhase 31318
44Contraceptives, OralPhase 31327
45Contraceptives, Oral, CombinedPhase 3636
46Estradiol 17 beta-cypionatePhase 31318
47FluoroquinolonesPhase 3392
48Estradiol valeratePhase 31318979-32-8
49
CisplatinapprovedPhase 2, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
50
AldesleukinapprovedPhase 2, Phase 140585898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human

Interventional clinical trials:

(show top 50)    (show all 95)
idNameStatusNCT IDPhase
1Glargine Versus NPH in Patients With Chronic Kidney DiseaseCompletedNCT02451917Phase 4
2Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the ProstateRecruitingNCT02749604Phase 4
3Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in ChinaRecruitingNCT02842749Phase 4
4Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
5The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes MellitusCompletedNCT00700817Phase 3
6Study of Paclitaxel in Patients With Ovarian CancerCompletedNCT00989131Phase 3
7Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)RecruitingNCT02718417Phase 3
8Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian CancerNot yet recruitingNCT03180177Phase 3
9Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantTerminatedNCT00324324Phase 3
10Oral Androgens in Man-4: (Short Title: Oral T-4)CompletedNCT00399165Phase 1, Phase 2
11Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial CarcinomaCompletedNCT01689714Phase 2
12Metformin Combined With Chemotherapy for Pancreatic CancerCompletedNCT01210911Phase 2
13Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic CancerCompletedNCT01064622Phase 1, Phase 2
14Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumCompletedNCT00896454Phase 2
15Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)CompletedNCT00635193Phase 1, Phase 2
16Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00334893Phase 2
17Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal CancerCompletedNCT00314678Phase 2
18Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2
19Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
20A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic CancerCompletedNCT00902291Phase 2
21Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic AdenocarcinomaCompletedNCT01146054Phase 2
22Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb TrialCompletedNCT01630018Phase 2
23A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) PatientsCompletedNCT01262235Phase 1, Phase 2
24High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00060255Phase 2
25A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel ChemotherapyCompletedNCT00603941Phase 1, Phase 2
26Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell TransplantationCompletedNCT00003887Phase 2
27Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With CancerCompletedNCT00003408Phase 2
28Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or ColonCompletedNCT00010283Phase 1, Phase 2
29Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantCompletedNCT00410657Phase 2
30A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)CompletedNCT01240590Phase 1, Phase 2
31Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1, Phase 2
32Study to Compare Cardiovascular Side Effects of Teysuno Versus CapecitabineRecruitingNCT01845337Phase 2
33Phase I/II Study of IMMU-132 in Patients With Epithelial CancersRecruitingNCT01631552Phase 1, Phase 2
34Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsRecruitingNCT02810418Phase 1, Phase 2
35Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic CancerRecruitingNCT03073785Phase 2
36Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic CancerRecruitingNCT01959672Phase 2
37Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell CancerRecruitingNCT02860819Phase 2
38Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1, Phase 2
39Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02101918Phase 2
40Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaActive, not recruitingNCT00531284Phase 1, Phase 2
41Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell TumorsActive, not recruitingNCT02499952Phase 2
42QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic CancerActive, not recruitingNCT01834235Phase 1, Phase 2
43Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by SurgeryNot yet recruitingNCT02973997Phase 2
44Gemcitabine and CT-011 for Resected Pancreatic CancerSuspendedNCT01313416Phase 2
45A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsTerminatedNCT00947167Phase 2
46IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by SurgeryTerminatedNCT00778817Phase 2
47Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian CancerTerminatedNCT00718523Phase 2
48Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid CancerTerminatedNCT00647140Phase 2
49QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid TumorsTerminatedNCT00819169Phase 1, Phase 2
50Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary EndpointTerminatedNCT00613730Phase 2

Search NIH Clinical Center for Multiple Endocrine Neoplasia, Type Iv

Genetic Tests for Multiple Endocrine Neoplasia, Type Iv

About this section

Genetic tests related to Multiple Endocrine Neoplasia, Type Iv:

id Genetic test Affiliating Genes
1 Multiple Endocrine Neoplasia, Type 427
2 Multiple Endocrine Neoplasia Type 424 CDKN1B

Anatomical Context for Multiple Endocrine Neoplasia, Type Iv

About this section

MalaCards organs/tissues related to Multiple Endocrine Neoplasia, Type Iv:

36
Thyroid, Pituitary, Cervix, Pancreas

Publications for Multiple Endocrine Neoplasia, Type Iv

About this section

Variations for Multiple Endocrine Neoplasia, Type Iv

About this section

Clinvar genetic disease variations for Multiple Endocrine Neoplasia, Type Iv:

5 (show all 19)
id Gene Variation Type Significance SNP ID Assembly Location
1RETNM_ 020975.4(RET): c.1901G> A (p.Cys634Tyr)SNVPathogenic/ Likely pathogenicrs75996173GRCh37Chr 10, 43609949: 43609949
2RETNM_ 020630.4(RET): c.1859G> A (p.Cys620Tyr)SNVPathogenic/ Likely pathogenicrs77503355GRCh37Chr 10, 43609103: 43609103
3RETNM_ 020975.4(RET): c.1900T> C (p.Cys634Arg)SNVPathogenic/ Likely pathogenicrs75076352GRCh37Chr 10, 43609948: 43609948
4RETNM_ 020630.4(RET): c.1902C> G (p.Cys634Trp)SNVPathogenic/ Likely pathogenicrs77709286GRCh37Chr 10, 43609950: 43609950
5RETNM_ 020975.4(RET): c.2753T> C (p.Met918Thr)SNVPathogenic/ Likely pathogenicrs74799832GRCh37Chr 10, 43617416: 43617416
6RETNM_ 020630.4(RET): c.1852T> C (p.Cys618Arg)SNVPathogenic/ Likely pathogenicrs76262710GRCh37Chr 10, 43609096: 43609096
7RETNM_ 020630.4(RET): c.2304G> C (p.Glu768Asp)SNVPathogenic/ Likely pathogenicrs78014899GRCh37Chr 10, 43613840: 43613840
8RETNM_ 020975.4(RET): c.1826G> A (p.Cys609Tyr)SNVPathogenic/ Likely pathogenicrs77939446GRCh37Chr 10, 43609070: 43609070
9RETNM_ 020975.4(RET): c.2671T> G (p.Ser891Ala)SNVPathogenic/ Likely pathogenicrs75234356GRCh37Chr 10, 43615592: 43615592
10CDKN1BNM_ 004064.4(CDKN1B): c.59_ 77dup19 (p.Ser27Glyfs)duplicationPathogenicrs786201007GRCh38Chr 12, 12717898: 12717916
11CDKN1BNM_ 004064.4(CDKN1B): c.206C> T (p.Pro69Leu)SNVPathogenicrs777354267GRCh38Chr 12, 12718045: 12718045
12CDKN1BNM_ 004064.4(CDKN1B): c.-456_ -453delCCTTdeletionPathogenicrs786201010GRCh37Chr 12, 12870318: 12870321
13CDKN1BNM_ 004064.4(CDKN1B): c.374_ 375delCT (p.Ser125Terfs)deletionPathogenicrs786201011GRCh37Chr 12, 12871147: 12871148
14RETNM_ 020975.4(RET): c.1853G> A (p.Cys618Tyr)SNVPathogenic/ Likely pathogenicrs79781594GRCh37Chr 10, 43609097: 43609097
15RETNM_ 020630.4(RET): c.1888T> C (p.Cys630Arg)SNVPathogenic/ Likely pathogenicrs377767404GRCh37Chr 10, 43609936: 43609936
16RETNM_ 020630.4(RET): c.2410G> C (p.Val804Leu)SNVPathogenic/ Likely pathogenicrs79658334GRCh37Chr 10, 43614996: 43614996
17RETNM_ 020975.4(RET): c.2647_ 2648delGCinsTT (p.Ala883Phe)indelPathogenic/ Likely pathogenicrs377767429GRCh37Chr 10, 43615568: 43615569
18CDKN1BNM_ 004064.4(CDKN1B): c.49_ 52delGACG (p.Asp17Profs)deletionPathogenicrs1060500186GRCh38Chr 12, 12717888: 12717891
19CDKN1BNM_ 004064.4(CDKN1B): c.227G> A (p.Trp76Ter)SNVPathogenicrs121917832GRCh37Chr 12, 12871000: 12871000

Expression for genes affiliated with Multiple Endocrine Neoplasia, Type Iv

About this section
Search GEO for disease gene expression data for Multiple Endocrine Neoplasia, Type Iv.

Pathways for genes affiliated with Multiple Endocrine Neoplasia, Type Iv

About this section

GO Terms for genes affiliated with Multiple Endocrine Neoplasia, Type Iv

About this section

Biological processes related to Multiple Endocrine Neoplasia, Type Iv according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of epithelial cell proliferationGO:005068010.4CDKN1B, MEN1
2negative regulation of phosphorylationGO:004232610.2CDKN1B, CDKN2C
3DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:000697710.0CDK2, CDKN1B
4negative regulation of cell proliferationGO:00082859.8CDKN1B, CDKN2C, MEN1
5negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:00457369.8CDKN1B, CDKN2C, MEN1
6regulation of cyclin-dependent protein serine/threonine kinase activityGO:00000799.5CDKN1B, CDKN2C
7G1/S transition of mitotic cell cycleGO:00000829.4CDK2, CDKN1B, CDKN2C
8phosphorylationGO:00163108.6CDK2, CDKN1B, CDKN2C, PRKAR1A

Molecular functions related to Multiple Endocrine Neoplasia, Type Iv according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486110.2CDKN1B, CDKN2C
2cyclin bindingGO:003033210.0CDK2, CDKN1B
3cyclin-dependent protein serine/threonine kinase activityGO:000469310.0CDK2, CDKN1B
4kinase activityGO:00163018.1CDK2, CDKN1B, CDKN2C, PRKAR1A

Sources for Multiple Endocrine Neoplasia, Type Iv

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet